Form 4: Seres Therapeutics Executive Lisa von Moltke Reports Stock Sales to Cover Taxes

Lisa von Moltke, Executive Vice President and Chief Medical Officer of Seres Therapeutics, reports the sale of common stock to cover taxes related to vesting restricted stock units.

Summary

• Lisa von Moltke, an executive at Seres Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 15, 2025, von Moltke acquired 2,969 shares and 8,907 shares of common stock through the vesting of restricted stock units.
• Also on February 15, 2025, 2,969 and 8,907 restricted stock units vested.
• On February 18, 2025, von Moltke sold 4,416 shares of common stock at a weighted average price of $0.8105 per share.
• The sales were executed under a Rule 10b5-1 plan adopted on March 11, 2023, to cover taxes associated with the vesting of restricted stock units.
• Following these transactions, von Moltke directly owns 39,875 shares of Seres Therapeutics common stock.
• She also owns 23,750 and 26,718 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock transactions by an executive for tax purposes, which is a routine activity.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment and confidence in the company.

Key Dates

Keywords

Form 4, Seres Therapeutics, MCRB, Lisa von Moltke, Stock Sale, Restricted Stock Units, Beneficial Ownership, Rule 10b5-1